

FIG. 1 (PRIOR ART)

MHPOVVIISLILHADSVAGSVKVGGEAGPSVTLPCHYSGAVITSMCWNRGCSLIFTCQNG 60
 IWTN~~Q~~EVTYRKDTRYKILLGDLSRDRDVSLTENTAVSDSGVYCCRVEHRGWENDMKITV 120
 SLEIVPPKVTTTPIVTTVPTVTTVPTVTTVPTVTTVPTVTTVPTVTTVPTVTTVPTVTTVPTV 180
 TTSVPTTTSIPTTSVPTVTTVSTFVPPMPTPRQNEPVATSPSSPQPAETHPTTQGA 240
 IRREPTSSPLYSYT'DGNE~~TT~~VTTESSDGLWNNT~~Q~~QOLFLEHSLITAT~~TT~~KGIYAGVCISVL 300
 VLALLGVIIAKKYYFFKKEVQQL{RPHKSCSIHQRE 334
 VLSFSSLIQIKALQNAVEKEVqaedniyTENSPLYATD 359 (SEQ ID NO:1)

FIG. 2 (PRIOR ART)

Ig-like domain




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7





FIG. 8



monoclonal antibodies






FIG. 9

FIG. 10



KIM-1-Ig and control fusion proteins

FIG. 11






FIG. 12A




FIG. 12B




FIG. 13

13/14




FIG. 14

14/14

FIG. 15A




FIG. 15B

